Zelnorm News
FDA will allow Zelnorm only when risks do not outweigh benefits
The Food and Drug Administration has announced that it will allow doctors to prescribe the irritable bowel syndrome drug Zelnorm to a limited number of patients for whom its benefits outweigh the risk of cardiovascular problems. The agency had asked the drug’s manufacturer, Novartis Pharmaceutical, to withdraw it from the market in March due to the potential risk of Zelnorm side effects.
Zelnorm-Recall.com Launched by Hissey Kientz, LLP
The law firm of Hissey Kientz, LLP has announced the launch of its new website, Zelnorm-Recall.com. This new site will provide patients with information about the potential health risks of Zelnorm, as well as medical and legal information concerning the recent recall of Zelnorm in the United States. More »
Group warned of Zelnorm side effects risk in 2001
The Food and Drug Administration should not have approved the irritable bowel syndrome (IBS) drug Zelnorm for sale, a consumer advocacy group says. According to a letter released by Public Citizen, the group warned of the risk of Zelnorm side effects in 2001, which it says includes heart problems, fainting and ovarian cysts. Zelnorm was withdrawn at the request of the FDA this week by its manufacturer, Novartis Pharmaceuticals, due to its risk of causing heart attack or stroke.
Novartis’ GI drug Zelnorm taken off the market
Zelnorm, the popular gastrointestinal medicine made by Swiss-based Novartis, is off the market. The Food and Drug Administration asked the company, and it agreed, to halt marketing and sales of the drug on the basis of recent findings of a heightened risk of serious heart problems.
Novartis agrees to halt sales of Zelnorm
Novartis AG, the Swiss pharmaceutical giant, has agreed to stop selling Zelnorm. This drug, which is intended to relieve constipation and irritable bowel syndrome, has been linked to a heightened risk of heart attack and stroke, according to the Food and Drug Administration.
Voluminous IBS problems seen with Zelnorm
Some people with irritable bowel syndrome (IBS) who take Zelnorm have suffered such serious diarrhea as to need hospitalization, according to the Food and Drug Administration. It ordered a change to the label of Zelnorm—an IBS precaution, along with a warning about severe diarrhea.